Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
CLDN18.2 positive
i
Other names:
CLDN18, Claudin-18, Surfactant, Pulmonary Associated Protein J, Surfactant Associated 5, SFTA5, SFTPJ
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
51208
Related biomarkers:
Expression
Fusion
‹
CLDN18.2 expression (30)
CLDN18.2 overexpression (6)
CLDN18.2 expression + HER-2 negative (2)
CLDN18.2 positive + HER-2 negative (2)
CLDN18.2 underexpression (2)
CLDN18.2 expression (30)
CLDN18.2 overexpression (6)
CLDN18.2 expression + HER-2 negative (2)
CLDN18.2 positive + HER-2 negative (2)
CLDN18.2 underexpression (2)
›
Associations
(14)
News
Trials
Search handles
@JDekervel
@drkpavithran
@pashtoonkasi
Search handles
@JDekervel
@drkpavithran
@pashtoonkasi
Filter by
Latest
9ms
The GLOW study is published! Kudos to the GI Oncology community and our patients. Zolbetuximab should be considered a standard option for CLDN18.2 positive gastroesophageal adenocarcinoma! @drallysonocean @pashtoonkasi @nyphospital @WCM_MeyerCancer https://t.co/G0wWPLz2Zr (@mdmanishshah)
9 months ago
Clinical
|
CLDN18 (Claudin 18)
|
CLDN18.2 positive
|
Vyloy (zolbetuximab)
11ms
Yes, the goal of this study is to provide a new treatment option for those with CLDN18.2 positive, HER2 negative advanced gastric or gastroesophageal junction adenocarcinoma to improve treatment outcomes and survival. (@QuintionDulles3)
11 months ago
Clinical • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
|
HER-2 negative • CLDN18.2 positive
1year
Zolbetuximab + mFOLFOX6 improves PFS (10·61 months vs 8·67 months) and OS in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or GE junction adenocarcinoma- SPOTLIGHT trial https://t.co/yYjg67tMQk (@drkpavithran)
1 year ago
Clinical • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
|
HER-2 negative • CLDN18.2 positive
|
5-fluorouracil • oxaliplatin • leucovorin calcium • Vyloy (zolbetuximab)
1year
Zolbetuximab plus mFOLFOX6 in patients with #CLDN18.2-positive, unresectable #gastriccancer or #esophagealcancer (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial @mdmanishshah @WCMGIcancer https://t.co/DDbaBVaWx0 (@DrDespina123)
1 year ago
Clinical
|
CLDN18 (Claudin 18)
|
CLDN18.2 positive
|
5-fluorouracil • oxaliplatin • leucovorin calcium • Vyloy (zolbetuximab)
1year
Zolbetuximab demonstrated a survival benefit when combined w/ mFOLFOX6 vs mFOLFOX6 + placebo in CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. @KoheiShitara #oncology https://t.co/QTlxT9EJ5s (@OncLive)
1 year ago
Clinical • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
|
HER-2 negative • CLDN18.2 positive
|
5-fluorouracil • oxaliplatin • leucovorin calcium • Vyloy (zolbetuximab)
1year
Zolbetuximab demonstrated a survival benefit when combined w/ mFOLFOX6 vs mFOLFOX6 + placebo in CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. @KoheiShitara #oncology https://t.co/bVbJF79yUs (@OncLive)
1 year ago
Clinical • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
|
HER-2 negative • CLDN18.2 positive
|
5-fluorouracil • oxaliplatin • leucovorin calcium • Vyloy (zolbetuximab)
over1year
Investigators report benefit in patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/GEJ adenocarcinoma treated with first-line zolbetuximab and mFOLFOX6. #gicsm #GI23 | @ASCO @KoheiShitara https://t.co/hmkyxtDxqK (@CancerNetwrk)
over 1 year ago
Clinical • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
|
HER-2 negative • CLDN18.2 positive
|
5-fluorouracil • oxaliplatin • leucovorin calcium • Vyloy (zolbetuximab)
over1year
👇🏾Adding another biomarker for upper GI: 💡All IHC🔬based 1️⃣HER2 2️⃣MMR 3️⃣CPS-PDL1 4️⃣FGFR2 5️⃣ #CLAUDIN 18.2 (CLDN18.2) #Zolbetuximab for CLDN18.2-positive, HER2-negative, unresectable or metastatic gastric or GEJ adenocarcinoma. #PrecisionMedicine #STCSM #ESOCSM @OncoAlert @ASCO https://t.co/c7IKJugLR1 (@pashtoonkasi)
over 1 year ago
IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • FGFR2 (Fibroblast growth factor receptor 2) • CLDN18 (Claudin 18)
|
HER-2 negative • CLDN18.2 positive
|
Vyloy (zolbetuximab)
over1year
Moving the needle in #GastricCancer. The addition of Zolbetuximab to FOLFOX in 1st line CLDN18.2 positive disease. ⬆️PFS ⬆️OS - eager to see full data https://t.co/mmMKp4Lkp5 (@JDekervel)
over 1 year ago
CLDN18 (Claudin 18)
|
CLDN18.2 positive
|
5-fluorouracil • leucovorin calcium • Vyloy (zolbetuximab)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login